Report #2828679

Received Feb 27, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: TX
Recovered: Unknown
Vaccinated: Aug 21, 2024
Onset: Aug 21, 2024
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	E3XT9	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

Shingrix early second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too short in a 67-year-old female patient who received Herpes zoster (Shingrix) (batch number E3XT9, expiry date 19-JUN-2026) for prophylaxis. Concomitant products included Varicella zoster vaccine rgE (CHO) (Shingrix). On 21-AUG-2024, the patient received the 2nd dose of Shingrix. On 21-AUG-2024, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too short (Verbatim: Shingrix early second dose). The outcome of the drug dose administration interval too short was not applicable. Additional Information: GSK Receipt Date: 25-FEB-2025 The pharmacist asked if a patient should be revaccinated with Shingrix after she had the second dose 50 days after the first dose which led to shortening of vaccination schedule. The vaccine administration facility was the same as primary reporter.

Other medications

SHINGRIX